This little-known pharma stock has more than 80% upside, and Citi says it's an attractive global stock

Citi Strategists Say Buy Dips in Global Stocks on Solid Earnings on solid Earnings. Global equities are more attractive after the recent rout removed market froth, strategists say. Investors focus on robust corporate earnings, according to Citigroup Inc. strategists.

Analyst Luca Issi began research coverage of the pharmaceutical company with an outperform rating. RBC: 'Buy this little-known pharma stock with more than 80% upside ahead, RBC says. The company develops treatments for rare and ultra-rare diseases.

Citi says this 'high risk' but 'attractive' global stock has 280% upside. The company has reportedly been the subject of takeover interest recently, partly due to its cheap valuation. Citi: 'High risk' stock has '280% upside. Citi calls it a 'high-risk' but attractive global stock.